Understanding how Raf Kinases work in cancer signaling
Chemical biological analysis of RAF Kinases
This study is looking at how certain proteins called Raf Kinases work in some cancers and how we can develop new treatments that target them, which could help patients with those specific types of cancer feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10995941 on NIH RePORTER |
What this research studies
This research investigates the role of Raf Kinases, which are important in cancer signaling pathways, particularly in cancers driven by mutant RAS. The team will analyze how different Raf isoforms interact and how they can be targeted with new drugs. By using advanced techniques like RNA barcoding, they aim to uncover the mechanisms that make Raf kinases sensitive or resistant to specific cancer treatments. This comprehensive analysis could lead to more effective therapies for patients with certain types of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are driven by mutant RAS and Raf signaling pathways.
Not a fit: Patients with cancers not associated with RAS or Raf signaling may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that specifically target Raf kinases, potentially enhancing patient outcomes.
How similar studies have performed: Previous research has shown promise in targeting Raf kinases in cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Maly, Dustin J — University of Washington
- Study coordinator: Maly, Dustin J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.